NASDAQ:GBIO

Generation Bio Competitors

$27.20
-1.44 (-5.03 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.10
Now: $27.20
$29.07
50-Day Range
$26.59
MA: $33.03
$40.20
52-Week Range
$17.00
Now: $27.20
$55.72
Volume690,640 shs
Average Volume696,524 shs
Market Capitalization$1.53 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Generation Bio (NASDAQ:GBIO) Vs. IONS, SRPT, ALLK, BPMC, PRGO, and SDGR

Should you be buying GBIO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Generation Bio, including Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), and Schrödinger (SDGR).

Generation Bio (NASDAQ:GBIO) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Generation Bio and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Generation BioN/AN/AN/A
Ionis Pharmaceuticals7.82%6.57%3.39%

Valuation & Earnings

This table compares Generation Bio and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation BioN/AN/AN/AN/AN/A
Ionis Pharmaceuticals$1.12 billion5.31$303.26 million$2.0820.37

Ionis Pharmaceuticals has higher revenue and earnings than Generation Bio.

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Generation Bio00603.00
Ionis Pharmaceuticals27602.27

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Ionis Pharmaceuticals has a consensus target price of $57.9091, indicating a potential upside of 36.71%. Given Generation Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Generation Bio is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats Generation Bio on 6 of the 8 factors compared between the two stocks.

Generation Bio (NASDAQ:GBIO) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Generation Bio and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Generation BioN/AN/AN/A
Sarepta Therapeutics-121.30%-61.62%-23.02%

Valuation & Earnings

This table compares Generation Bio and Sarepta Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation BioN/AN/AN/AN/AN/A
Sarepta Therapeutics$380.83 million14.71$-715,080,000.00($9.71)-7.26

Generation Bio has higher earnings, but lower revenue than Sarepta Therapeutics.

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Sarepta Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Generation Bio00603.00
Sarepta Therapeutics191202.50

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Sarepta Therapeutics has a consensus target price of $150.4762, indicating a potential upside of 113.32%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Generation Bio.

Summary

Sarepta Therapeutics beats Generation Bio on 5 of the 9 factors compared between the two stocks.

Generation Bio (NASDAQ:GBIO) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Generation Bio and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Generation BioN/AN/AN/A
AllakosN/A-29.18%-27.70%

Valuation & Earnings

This table compares Generation Bio and Allakos' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation BioN/AN/AN/AN/AN/A
AllakosN/AN/A$-85,370,000.00($1.89)-55.56

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Allakos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Generation Bio00603.00
Allakos00403.00

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Allakos has a consensus target price of $181.50, indicating a potential upside of 72.86%. Given Allakos' higher probable upside, analysts plainly believe Allakos is more favorable than Generation Bio.

Generation Bio (NASDAQ:GBIO) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Generation Bio and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Generation BioN/AN/AN/A
Blueprint Medicines41.08%43.72%33.35%

Valuation & Earnings

This table compares Generation Bio and Blueprint Medicines' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation BioN/AN/AN/AN/AN/A
Blueprint Medicines$66.51 million82.05$-347,690,000.00($7.27)-12.95

Generation Bio has higher earnings, but lower revenue than Blueprint Medicines.

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Blueprint Medicines, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Generation Bio00603.00
Blueprint Medicines06712.64

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Blueprint Medicines has a consensus target price of $111.00, indicating a potential upside of 17.88%. Given Generation Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Generation Bio is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats Generation Bio on 7 of the 10 factors compared between the two stocks.

Generation Bio (NASDAQ:GBIO) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Perrigo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Generation Bio00603.00
Perrigo04102.20

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Perrigo has a consensus target price of $52.00, indicating a potential upside of 28.30%. Given Generation Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Generation Bio is more favorable than Perrigo.

Valuation & Earnings

This table compares Generation Bio and Perrigo's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation BioN/AN/AN/AN/AN/A
Perrigo$4.84 billion1.12$146.10 million$4.0310.06

Perrigo has higher revenue and earnings than Generation Bio.

Profitability

This table compares Generation Bio and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Generation BioN/AN/AN/A
Perrigo-0.13%9.78%4.92%

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Perrigo beats Generation Bio on 5 of the 9 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Generation Bio (NASDAQ:GBIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Schrödinger and Generation Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Generation Bio00603.00

Schrödinger presently has a consensus price target of $85.50, indicating a potential upside of 15.70%. Generation Bio has a consensus price target of $40.60, indicating a potential upside of 49.26%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Generation Bio is more favorable than Schrödinger.

Earnings & Valuation

This table compares Schrödinger and Generation Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million60.48$-24,570,000.00N/AN/A
Generation BioN/AN/AN/AN/AN/A

Generation Bio has lower revenue, but higher earnings than Schrödinger.

Profitability

This table compares Schrödinger and Generation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Generation BioN/AN/AN/A

Institutional and Insider Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 63.3% of Generation Bio shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Generation Bio beats Schrödinger on 7 of the 8 factors compared between the two stocks.


Generation Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.54-1.3%$5.60 billion$380.83 million-9.02
Allakos logo
ALLK
Allakos
1.7$105.00-2.9%$5.58 billionN/A-38.32Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16-0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90-4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81-0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
News Coverage
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.